Successfully navigate translational biology and phenotypic assay approaches to compound screening with Eurofins Discovery’s cell-based functional assays employing a human-focused approach to drug discovery.
Inclusion of cell-based phenotypic assays in drug discovery screening cascades is increasingly popular, with the readout of those phenotypic screening assays often being cellular secretions or measurement of native or promiscuous secondary messenger systems.
Gain an advantage in this process by partnering with Eurofins Integrated Discovery and Eurofins Genomics to utilize the Fluidigm microfluidics-based qPCR technology to interrogate gene expression in support of drug discovery screening. Gene expression assays may be an essential part of your screening cascade for the development of Nuclear Hormone Receptors as a target, investigating downstream effects of receptor or enzyme modulation or conducting target validation studies.
Our experienced team can assist your search by running a custom assay with your specified cell lines or primary cells mulitplexing up to 8 genes. Our unique 96-well format reduces reagent costs, especially when purchasing primary cell types. Screening can be single-concentration or full curves in both agonist and antagonist modes. And if required we can also couple your gene expression assay to a biomarker measurement. Benefits include:
- Gene expression modulators assayed over an 8-point concentration range to generate an EC50 or as single concentrations for library screening
- 96-well format
- Validated for cell lines – HepG2 (human hepatocytoma), THP-1 (human monocyte), A375 (human melanoma) and U2OS (human oesteosarcoma)
- Validated for primary cells – human hepatocytes, human macrophages
- Other cell types can be utilised simply by running an RNA yield optimization step
